Gain Therapeutics, Inc. (GANX) Stock Forecast
GANX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.80 / 5 from 5 analysts
- Price target
- $7.20 average of analyst targets
- Upside to target
- +471.4% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.13
- 52-week range
- $1.26 – $4.18
GANX analyst ratings
5 analystsNumber of analysts at each rating.
GANX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
GANX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.13 | −$0.13 | −$0.12 | −$0.15 | +15.0% | 4 |
| Current fiscal year (2026) | −$0.51 | −$0.53 | −$0.48 | −$0.61 | +17.2% | 4 |
| Next fiscal year (2027) | −$0.69 | −$1.11 | −$0.49 | −$0.51 | −36.1% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
GANX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 5 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 5 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 5 |
GANX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
GANX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.16 | −$0.16 | −$0.13 | −$0.13 | −$0.13 | −19.0% | 0 up · 0 down |
| Current fiscal year (2026) | −$0.60 | −$0.60 | −$0.50 | −$0.50 | −$0.51 | −16.2% | 0 up · 0 down |
| Next fiscal year (2027) | −$0.60 | −$0.60 | −$0.55 | −$0.55 | −$0.69 | +14.6% | 2 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
GANX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; GANX beat in 9 of 12.
What analysts expect from GANX
5 analysts cover Gain Therapeutics; their consensus rating is strong buy (4.80 on a 1–5 scale, where 5 is a strong buy). The average price target is $7.20, 471.4% above the latest close of $1.26. Analysts expect earnings of −$0.51 per share for 2026, +17.2% from a year earlier. For 2027 the average estimate is −$0.69 per share. Gain Therapeutics beat the EPS estimate in 9 of the last 12 quarters.
Related: GANX income statement, GANX key metrics, GANX chart. See the GANX stock overview for the latest quote and news.
GANX forecast FAQ
What is Gain Therapeutics's price target?
The average analyst price target for Gain Therapeutics is $7.20, 471.4% above the latest close of $1.26.
Is Gain Therapeutics a buy, hold or sell?
Of 5 analysts covering Gain Therapeutics, 4 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Gain Therapeutics's EPS forecast?
Analysts forecast −$0.51 per share for 2026 (range −$0.53 to −$0.48); for 2027 the estimate is −$0.69.
When does Gain Therapeutics report earnings?
Gain Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.13.
Does Gain Therapeutics usually beat earnings estimates?
Gain Therapeutics reported EPS at or above the analyst estimate in 9 of the last 12 quarters.